首页> 美国卫生研究院文献>Blood Cancer Journal >High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy

【2h】

High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy

机译：可溶性白细胞介素2受体的高预处理水平是接受R-CHOP样疗法治疗的滤泡性淋巴瘤患者的有力预后因素

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Blood Cancer Journal
作者
Y Kusano; M Yokoyama; Y Terui; N Inoue; A Takahashi; H Yamauchi; N Tsuyama; N Nishimura; Y Mishima; K Takeuchi; K Hatake;
展开▼
作者单位

展开▼
年(卷),期 2017(7),9
年度 2017
页码 e614
总页数 3
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy [J] . Y Kusano, M Yokoyama, Y Terui, Blood cancer journal. . 2017 ,第9期

机译：可溶性白细胞介素2受体的高预处理水平是使用R-CHOP样疗法治疗的滤泡性淋巴瘤患者的强有力的预后因素
2. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era [J] . ProcházkaV., PapajíkT., FaberE., Leukemia and lymphoma . 2014 ,第7期

机译：可溶性白细胞介素2受体水平预测利妥昔单抗时代用环磷酰胺，阿霉素，长春新碱和泼尼松化疗治疗的滤泡性淋巴瘤患者的生存
3. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. [J] . Oki Y, Kato H, Matsuo K, Leukemia and lymphoma . 2008 ,第7期

机译：血清可溶性白介素2受体水平在弥散性大B细胞淋巴瘤患者中的预后价值，采用基于CHOP或RCHOP的治疗。
4. PET WITH ~(18)FDG AND SPECT WITH ~(99)Tc~m-SESTAMIBI FOR THERAPY MANAGEMENT IN PATIENTS WITH TREATED MALIGNANT LYMPHOMAS [C] . L.G. STRAUSS, A. DIMITRAKOPOULOU-STRAUSS, H. GOLDSCHMIDT, Tomography in nuclear medicine . 1995

机译：含〜（18）FDG的PET和含〜（99）Tc〜m-SESTAMIBI的SPECT用于治疗恶性淋巴瘤的患者的治疗
5. Prognostic Biomarkers for Diffuse Large B Cell Lymphoma Patient Survival after Treatment with Chemotherapy: A Retrospective Analysis of 88 Cases [D] . Bushra, Hamama tul. 2019

机译：弥漫性大B细胞淋巴瘤化疗后患者生存的预后生物标志物：88例回顾性分析
6. MIB‐1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy [O] . Eri Yamamoto, Naoto Tomita, Seiji Sakata, 2013

机译：MIB-1标记指数作为用Rituximab Plus Chec疗法治疗卵泡淋巴瘤患者的预后因素
7. High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy [O] . Y Kusano, M Yokoyama, Y Terui, 2017

机译：可溶性白细胞介素-2受体的高预处理水平是用R-Chootph样疗法治疗的滤泡淋巴瘤患者的稳健预后因子

High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy

著录项

相似文献

相关主题

期刊订阅